Preparing a marketing authorisation application for the European Union can be costly when documentation is incomplete, submission requirements are misunderstood or critical deadlines are approaching. Validation problems and repeated requests for clarification may disrupt planned regulatory milestones and delay market entry. With expert regulatory affairs support from Billev Pharma East, pharmaceutical and biotechnology companies can identify dossier weaknesses early and coordinate preparation for an EU submission.

What must pharmaceutical companies do before submitting a marketing authorisation application?

Before submitting a marketing authorisation application, pharmaceutical companies must establish a suitable legal basis and authorisation pathway, assemble the supporting evidence and verify that the dossier meets the applicable EU requirements. Both the scientific information and the administrative arrangements must be complete and consistent.

A first decision is whether the medicinal product is eligible for the centralised procedure or should follow an applicable decentralised, mutual recognition or national pathway. The company must also establish which data are required for its application type. Requirements differ, for example, between a full dossier and an application relying on an established legal basis with specific data provisions. A clear regulatory strategy should guide these decisions, but it does not replace dossier preparation.

Companies then need to coordinate quality, non-clinical, clinical and product information from internal teams and external contributors. Manufacturing details, administrative declarations, proposed product information and evidence summaries should be consistent across the dossier. Submission planning must account for authority-specific steps, technical specifications, dossier finalisation, available resources and realistic deadlines. Where relevant, applicants should also organise pre-submission interactions and clarify eligibility questions in good time.

Before filing, the applicant should review the final dossier for gaps, inconsistencies and technical errors, and establish who will respond to authority questions. Preparation cannot guarantee authorisation, but it can help validation and assessment proceed efficiently.

How can Billev Pharma East help you prepare your marketing authorisation application?

Billev Pharma East helps pharmaceutical and biotechnology companies plan their submissions around European regulatory requirements. Our Regulatory Affairs specialists support the preparation and review of your marketing authorisation application from an early stage, so dossier gaps can be addressed before the filing deadline.

Our support is tailored to the product, regulatory procedure and capabilities of the applicant. We can help assess the applicable registration route, identify the required documentation, review and coordinate dossier content, support preparation of regulatory documents and assist with submission-related communications. We check for consistency in the information supplied by scientific, quality, manufacturing and regulatory contributors. This helps identify documentation problems before authority validation.

For companies facing a temporary workload peak or lacking a comprehensive in-house team, our regulatory outsourcing services provide access to specialist resources. Clients can retain oversight of key decisions while receiving practical assistance with execution, coordination and follow-up. We can support specific work packages or broader registration projects.

Billev Pharma East can help organise your submission work before problems put deadlines at risk. We help improve application readiness and manage communication with authorities.

What are the key considerations when preparing a marketing authorisation application?

A marketing authorisation application must be built around a defensible legal basis, reliable scientific evidence and coherent documentation. Companies should assess these elements together, because the regulatory route determines what supporting information is necessary and how it should be presented. A dossier that is neatly formatted but lacks the data required for its legal basis is not submission-ready.

Check that the product description, pharmaceutical quality information, evidence summaries and proposed product information remain consistent across the dossier. Seemingly small differences in composition, manufacturing descriptions or product particulars can raise questions during validation. It is equally important that the applicant understands which data are applicable, which are not, and how any omissions or literature-based justifications should be explained.

For quality-related content, a targeted CMC assessment can identify weaknesses in information on active substances, finished product manufacturing, controls, specifications or stability. The findings must also be assessed for their impact on the rest of the application. Where multiple parties contribute data, version control, document ownership and a clear review process are particularly valuable.

Practical preparation also includes establishing the intended submission date, identifying relevant authority requirements and allowing time for final dossier compilation and internal approval. Billev Pharma East helps coordinate these activities and prioritise deficiencies that could affect submission readiness.

Which documents are required for a marketing authorisation application in the EU?

The documentation required for a marketing authorisation application depends on the legal basis, medicinal product and authorisation procedure. In general, the EU Common Technical Document (CTD) organises administrative information, scientific summaries, pharmaceutical quality information and the applicable non-clinical and clinical evidence into a consistent dossier structure.

EU-specific Module 1 includes the relevant administrative material, the electronic application form and proposed product information, together with other applicable declarations and documentation. Module 2 contains overviews and summaries of the scientific evidence. Module 3 describes pharmaceutical quality, including manufacturing and control information. Modules 4 and 5 provide the applicable non-clinical study reports and clinical study information. However, applicants should not assume that every application requires an identical set of studies: the applicable legal basis determines the evidence requirements.

These components must be reviewed as a single submission. Product composition and manufacturing information, for example, should align with the application form and proposed SmPC. A late change to one document may require corresponding updates elsewhere. Our guide to eCTD modules explains dossier organisation in more detail.

Billev Pharma East supports clients with documentation planning, compilation coordination and regulatory review. We help determine where information is missing, where cross-references are unclear and which documents require attention before filing.

Which EU authorisation procedure is appropriate for your medicinal product?

Choosing the appropriate authorisation procedure is an essential step in preparing a marketing authorisation application, because the available route depends on the medicine and its existing authorisation status. The centralised procedure is mandatory for certain medicines and available to other eligible products; successful centralised authorisation results in a Union-wide marketing authorisation. Other medicines may be authorised through relevant national, decentralised or mutual recognition procedures.

The decentralised procedure generally applies when an eligible medicinal product has not yet been authorised in any Member State and the applicant seeks authorisation in several participating states at once. The mutual recognition procedure builds on an existing national authorisation and seeks recognition in additional Member States. A national procedure is relevant where authorisation is sought in one Member State and a Union-wide procedure is not mandatory. The centralised procedure has distinct eligibility and pre-submission arrangements set out in EMA guidance.

An incorrect assumption about eligibility, the legal basis or the proposed market scope can undermine the project timetable before the dossier is submitted. A company expanding from outside Europe may benefit from a focused discussion of its specific product and planned markets with an experienced regulatory affairs consultant before committing to submission milestones.

Billev Pharma East can help evaluate the regulatory route, coordinate the required procedural preparation and align dossier work with the selected pathway.

How can companies reduce validation delays during the application process?

Treat dossier readiness as a project milestone, with time for review before filing. For a centralised marketing authorisation application, EMA carries out technical validation and then regulatory and administrative content validation. A technically invalid submission that is not corrected by the intended deadline can postpone the start of the procedure.

Companies should therefore confirm the applicable electronic format and technical standards, verify that administrative forms and dossier modules are complete, and assess consistency between key product details. EMA guidance specifically highlights alignment of the application form, dossier modules and SmPC. Applicants should also consider whether the intended filing date allows sufficient time for internal quality checks, document sign-off and timely correction of technical issues.

The work also depends on effective version control. When files are revised repeatedly by different teams, an incorrect document version or a mismatched cross-reference may enter the final package. Understanding eCTD lifecycle management helps companies maintain traceability of submission sequences, while the initial MAA still requires its own rigorous readiness review.

Billev Pharma East supports clients in reviewing the submission package, coordinating information from contributors and preparing for regulatory authority interactions. We aim to identify and resolve documentation problems before filing. Expert review cannot prevent every question or control assessment timelines, but it can help reduce administrative and technical setbacks.

When should companies seek external regulatory expertise?

External support is most valuable when a company begins to define the regulatory route and documentation plan for its marketing authorisation application, particularly if the internal team is small, deadlines are demanding or the dossier involves complex products and multiple contributors. Early engagement leaves more time to address substantive issues and set a realistic work schedule.

Some companies need help with an entire registration project, while others require specialist input on a limited set of activities. Targeted support from a CMC advisor may help resolve pharmaceutical quality questions. Broader Regulatory Affairs support may be needed to coordinate administrative requirements, the selected procedure, proposed product information and submission planning. These roles should work together rather than duplicate each other.

Outsourcing is also useful when an applicant is unfamiliar with EU submission practices or is managing several parallel projects. It enables internal teams to concentrate on development, manufacturing and business priorities while drawing on relevant regulatory experience. However, the applicant remains responsible for the accuracy and completeness of its application and should retain clear decision-making and oversight arrangements.

Billev Pharma East can tailor support to your needs, from a focused review to coordinated dossier preparation and submission assistance.

Frequently asked questions about marketing authorisation applications

Ready to move your marketing authorisation application forward?

A well-prepared marketing authorisation application depends on accurate documentation, coordinated preparation and a clear understanding of the EU regulatory pathway. Addressing gaps early can help keep the submission on schedule.

Billev Pharma East offers tailored Regulatory Affairs support for pharmaceutical and biotechnology companies preparing European submissions. Speak to our specialists about a readiness review, dossier coordination or application preparation for your project.

Sources: 1 – European Medicines Agency (EMA). (2026). Pre-authorisation guidance, 2 – European Commission. (n.d.). EudraLex – Volume 2: Notice to applicants and regulatory guidelines for medicinal products for human use, 3 – European Commission. (n.d.). EudraLex: EU legislation.